Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Carbon Changes Everything!!
View:
Post by biggdogg on Feb 05, 2024 6:15pm

Carbon Changes Everything!!

Generating revenue from carbon capture is huge. Check out fullerene in this video, https://www.youtube.com/watch?v=1wd_lC-nVlE
Comment by WarrantOfficer on Feb 06, 2024 9:17am
I concur biggdogg, but we must continue with our current strategic planning of full barium product release in Q2. IMO, this is paramount. Iodine has been pushed out to 2029. Carbon based drugs are at a minimum  6 - 10 years away. Current value of this company is based upon their current product line. Perhaps once the full line of barium products are available and sales begin to flow, a ...more  
Comment by biggdogg on Feb 06, 2024 3:25pm
Carbon will finance their company once it is turned on. They get paid to produce carbon, it will be more valuable than spherical graphite, this is what everyone seems to not understand, they are going to produce more carbon than a graphite mine. A 1MW diesel generator puts out 10,000 tonnes a day CO2, 2,800 tonnes a day carbon production. What is a tonne of "Engineered Carbon" worth? I ...more  
Comment by WarrantOfficer on Feb 07, 2024 9:18am
Credibility biffdogg Credibility. There will be zero loans without any credibility. 
Comment by WarrantOfficer on Feb 07, 2024 9:21am
Biggdogg my apologies...spelt out yur name incorrectly / whiile not checking before hitting the send button. 
Comment by biggdogg on Feb 08, 2024 10:59am
I Like That, BiffDogg, it has a good ring to it. Warrant Officer, you are always on point and are one of the most credible bull boarders on the site, you see clearly what this company needs to do to get their act together. The more research I do on C60 the more I beleive Carbon is their biggest asset with largest upside moving morward. Check out this review of C60. https://www.youtube.com ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1